



Bristol-Myers Squibb Pharma EEIG

Uxbridge Business Park, Sanderson Road
Uxbridge Middlesex UB8 1DH,
England

Registered in Cardiff, No GE87

Dr Eric Abadie
Chairman of CHMP
European Medicines Agency
7 Westferry Circus
Canary Wharf
London E14 4HB
United Kingdom

22 May 2008

Re: Withdrawal of DuoCover[®] (fixed-dose combinations tablets of 75 mg clopidogrel / 75 mg acetyl salicylic acid and 75 mg clopidogrel / 100 mg acetyl salicylic acid) marketing authorization application
DuoCover[®]: EMEA/H/C/000875

Dear Dr. Abadie,

I would like to inform you that, at this point of time, Bristol-Myers Squibb Pharma EEIG has taken the decision to withdraw the application for the marketing authorisation for DuoCover[®] (fixed-dose combination tablets of 75 mg clopidogrel / 75 mg acetyl salicylic acid and 75 mg clopidogrel / 100 mg acetyl salicylic acid), which was intended to be used as substitution therapy replacing clopidogrel and acetyl salicylic acid as separate compounds for the approved indication of prevention of atherothrombotic events in acute coronary syndrome (non-ST segment elevation acute coronary syndrome and ST segment elevation acute myocardial infarction).

This withdrawal is based on the CHMP's request regarding the need to document bioequivalence based on clopidogrel plasma levels in accordance with the Questions & Answers on the Bioavailability and Bioequivalence Guideline (EMA/CHMP/EWP/40326/2006). To address the CHMP's request Bristol-Myers Squibb Pharma EEIG intends to perform a new bioequivalence study measuring plasma levels of clopidogrel parent compound. However, the results of that study will unfortunately not be available in the timelines defined by the Centralised Procedure.

We reserve the right to make further submissions at a future date for this fixed-dose combination of clopidogrel and acetyl salicylic acid in the approved indication.

We agree for this letter to be published on the EMA website.

Yours sincerely,

Mailing address:

Parc de l'Alliance, Avenue de Finlande 8, B – 1420 Braine-l'Alleud, Belgium
Tel.: 32 2 352 79 27 – Fax.: 32 2 352 71 79